Philipponnet Carole, Aniort Julien, Pereira Bruno, Azarnouch Kazra, Hadj-Abdelkader Mohammed, Chabrot Pascal, Heng Anne-Elisabeth, Souweine Bertrand
Nephrology, Dialysis and Transplantation Department, CHU Clermont Ferrand, Clermont Ferrand, France.
Department of Clinical Research and Innovation (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France.
Kidney Int Rep. 2020 Apr 17;5(7):1000-1006. doi: 10.1016/j.ekir.2020.04.006. eCollection 2020 Jul.
The last decade has seen a steady increase worldwide in the prevalence of end-stage renal disease (ESRD). Hemodialysis is the major modality of renal replacement therapy (RRT) in 70% to 90% of patients, who require well-functioning vascular access for this procedure. The recommended access for hemodialysis is an arteriovenous fistula or a vascular graft. However, recourse to central venous catheters remains essential for patients whose chronic renal disease is diagnosed at the end stage or in whom an arteriovenous fistula cannot be created or maintained. Tunneled dialysis catheter (TDC) exposure can induce venous stenosis and occlusions and can result in superior vena cava syndrome and/or vascular access loss. Exhaustion of conventional vascular accesses is 1 of the greatest challenges that nephrologists and patients have to face. Several unconventional salvage-therapy routes for TDC placement in patients with exhausted upper body venous access have been reported in the literature.
We report 2 new cases of intra-atrial TDC placement for patients with exhausted vascular access and perform a meta-analysis of cases from the literature.
A total of 51 patients were included. The TDC was inserted by a cardiovascular surgeon in all cases. At the end of follow-up, 75% patients were alive. The median survival time was 25 months. Survival time of hemodialysis patients with intra-atrial TDC was lower than that observed with conventional TDC.
This unconventional technique is safe and functional for hemodialysis patients with exhausted venous access. Atrial vascular access for TDC placement is salvage therapy and is therefore potentially lifesaving.
在过去十年中,全球范围内终末期肾病(ESRD)的患病率稳步上升。血液透析是70%至90%患者肾脏替代治疗(RRT)的主要方式,而该治疗过程需要功能良好的血管通路。血液透析推荐使用的血管通路是动静脉内瘘或血管移植物。然而,对于那些在终末期被诊断为慢性肾病或无法建立或维持动静脉内瘘的患者,中心静脉导管仍是必不可少的。隧道式透析导管(TDC)外露可导致静脉狭窄和闭塞,并可能导致上腔静脉综合征和/或血管通路丧失。传统血管通路的耗尽是肾病学家和患者必须面对的最大挑战之一。文献中已报道了几种针对上身静脉通路耗尽的患者进行TDC置入的非常规挽救治疗途径。
我们报告了2例血管通路耗尽患者进行心房内TDC置入的新病例,并对文献中的病例进行了荟萃分析。
共纳入51例患者。所有病例均由心血管外科医生插入TDC。随访结束时,75%的患者存活。中位生存时间为25个月。心房内TDC血液透析患者的生存时间低于传统TDC患者。
这种非常规技术对于静脉通路耗尽的血液透析患者是安全且有效的。心房血管通路用于TDC置入是一种挽救治疗,因此可能挽救生命。